HC Wainwright Issues Positive Forecast for AVXL Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share estimates for shares of Anavex Life Sciences in a research note issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.13) for the quarter, up from their prior forecast of ($0.18). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.52) EPS, Q1 2026 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.49) EPS.

Separately, D. Boral Capital restated a “buy” rating and set a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Stock Down 0.6%

NASDAQ:AVXL opened at $8.32 on Friday. Anavex Life Sciences has a 52 week low of $3.51 and a 52 week high of $14.44. The stock has a market capitalization of $710.30 million, a PE ratio of -15.13 and a beta of 0.82. The stock’s 50-day moving average price is $8.89 and its 200-day moving average price is $9.11.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. During the same period last year, the firm earned ($0.13) EPS.

Institutional Investors Weigh In On Anavex Life Sciences

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Anavex Life Sciences by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 4,902,246 shares of the biotechnology company’s stock worth $42,061,000 after buying an additional 221,802 shares during the last quarter. Nwam LLC boosted its holdings in Anavex Life Sciences by 9.6% in the 1st quarter. Nwam LLC now owns 1,000,351 shares of the biotechnology company’s stock worth $8,583,000 after buying an additional 87,300 shares during the last quarter. Northern Trust Corp boosted its holdings in Anavex Life Sciences by 1.6% in the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company’s stock worth $7,592,000 after buying an additional 10,938 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Anavex Life Sciences by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company’s stock worth $7,273,000 after buying an additional 11,239 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Anavex Life Sciences by 2,419.8% in the 4th quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company’s stock worth $6,606,000 after buying an additional 590,639 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.